Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Cancer remains one of the leading causes of morbidity and mortality in the world. In 2018, there were an estimated 17.0 million cases of cancer diagnosed around the world and 9.5 million cancer deaths. By 2040, the global burden is expected to reach 27.5 million new cancer cases and 16.2 million cancer deaths. Fighting cancer and treating this growing number of patients with the latest medical advances is a central goal for medical professionals and healthcare policymakers. Approximately 52% of new cancer patients will need radiation therapy as part of the multi-disciplinary cancer care, and 23% of these patients will require reirradiation treatment.
Although photons are the most common source of ionizing radiation, protons are gaining increasing recognition from physicians and medical physicists as an advanced treatment modality. The growing emphasis on evidence-based medicine practice makes it worthwhile to assess the available evidence supporting proton therapy (PT) over other available techniques, so as to better guide physicians and patients toward the most appropriate treatment. It is estimated that in 2020, 85,720 new cases of Lymphoma will be diagnosed in the United States, including both adult and children and of which 8,480 Hodgkin Lymphoma (HL) and 77,240 Non-Hodgkin Lymphoma (NHL).
This white paper aims at providing existing clinical data on proton therapy for lymphomas, which can serve as a valuable reference when considering treatment options that would be of most benefit to patients.
IBA White Paper
*Please refer to the Terms and Conditions of this website when leaving the site and viewing third party content.